Infliximab-Associated Psoriasiform Dermatitis: Case Report and Review of a Seemingly Paradoxical Inflammatory Response

Background: Tumor necrosis factor-α (TNF-α) inhibitors, such as infliximab, adalimumab, and certolizumab pegol are effective agents in the treatment of inflammatory bowel disease. Some individuals undergoing anti-TNF-α therapy for Crohn’s disease or ulcerative colitis develop psoriasiform lesions. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Loh, Tiffany Y, Cohen, Philip R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2016
Materias:
Gastroenterology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059146/
https://www.ncbi.nlm.nih.gov/pubmed/27738572
http://dx.doi.org/10.7759/cureus.773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5059146/
https://www.ncbi.nlm.nih.gov/pubmed/27738572
http://dx.doi.org/10.7759/cureus.773

Ejemplares similares